Arndt A, Neumann C, Riecke A, Bauer A, et al. Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma. Oncologist 2025;30:oyae143.
PMID: 38960389